title: Cardiovascular and renal effects of calcitonin gene-related peptide in hypertensive dogs.
abstract: The systemic cardiovascular and renal effects of synthetic beta-human calcitonin gene-related peptide (beta-hCGRP) were examined in conscious normotensive and one-kidney one-clip (1K-1C) hypertensive dogs. beta-hCGRP was infused intravenously at 10 and 50 ng/kg/min for 75-min periods each. Mean arterial pressure did not change significantly (p greater than 0.05) in either group during low dose infusion of beta-hCGRP, but infusion of beta-hCGRP at 50 ng/kg/min produced a fall in mean arterial pressure from 140 +/- 4 to 116 +/- 6 mmHg (p less than 0.05) in the hypertensive dogs (n = 4) and from 100 +/- 4 to 78 +/- 3 mmHg (p less than 0.05) in the normotensive dogs (n = 4). Heart rates increased significantly during infusion of beta-hCGRP in both groups. Also, renal sodium and potassium excretion decreased (p less than 0.05) in the two groups at both the low and high doses of beta-hCGRP. Creatinine clearance was unchanged in normal dogs and decreased (p less than 0.05) in 1K-1C hypertensive dogs at the high rate of beta-hCGRP infusion. The clearance of p-aminohippurate increased approximately 20% (p less than 0.05) in both groups with the low dose infusion of beta-hCGRP but further increases were elicited only in the normotensive dogs in response to the elevation in the beta-hCGRP infusion rate. Plasma renin and aldosterone levels increased (p less than 0.05) above control levels during the maximum hypotensive response to beta-hCGRP infusion in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology, University of Missouri School of Medicine, Columbia, MO.
authors.forename: K M
authors.initials: KM
authors.lastname: Verburg
authors.forename: R H
authors.initials: RH
authors.lastname: Freeman
authors.forename: D
authors.initials: D
authors.lastname: Villarreal
authors.forename: M W
authors.initials: MW
authors.lastname: Brands
mesh_terms: D000450:Aldosterone / Q000097:blood; D000818:Animals; D002116:Calcitonin / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006978:Hypertension, Renovascular / Q000503:physiopathology*; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology*; D011188:Potassium / Q000097:blood / Q000652:urine; D012079:Renal Circulation / Q000187:drug effects*; D012083:Renin / Q000097:blood; D012964:Sodium / Q000097:blood / Q000652:urine; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D009479:Neuropeptides; D000450:Aldosterone; D002116:Calcitonin; D012964:Sodium; D012083:Renin; D015740:Calcitonin Gene-Related Peptide; D011188:Potassium